MUSCULOSKELETAL CLINICAL RESEARCH

Clinical trials in musculoskeletal disorders

Our clinical research associates (CRAs) in musculoskeletal disorders are highly trained professionals who ensure integrity and commitment to excellence.

Pepgra will give you the right data when you need it the most. Our experts have extensive experience in researching muscle, bone, and joint conditions.

We have supported studies evaluating low back pain, fibromyalgia, osteoarthritis, and rheumatoid arthritis. Monitoring, site visits, technical support, assessments—these are the some of our key offerings in Musculoskeletal and Skin Diseases. Moreover, we liaise with the data and safety monitoring teams for a portfolio of extramurally funded clinical trials.

Merits of our study in musculoskeletal disorders include, but not limited to the following:

The following are the merits of our oncology clinical research:

  • Monitoring and training
  • Chalking out research study tools
  • Data maintenance and reports (DSMB report template)
  • Regulatory writing, reporting & analysis
  • Data and Safety Monitoring Board (DSMB) coordination
  • Assistance for safety
  • Investigator meeting support
  • Post-marketing assistance (PMA)
  • Advice on regulatory protocols and approvals

Call us to find out how our CRAs can help you a specific area or if you want to participate in a clinical trial.

pepgra company-brochure
Brochure

Biostatistical capabilities

We give solutions to the healthcare, pharmaceuticals and food industries to boost sophistication of statistical elements in their study…. Read More
pepgra whitepapper
White Paper

Clinical evaluations

Clinical Evaluation Report (CER) in a more Stringent Regulatory Environment- Now, subject to more intense scrutiny by Noti¬fied Bodies…
Big Data in IoT for Healthcare Read More
pepgra case-study
Blog

Medical writing

The requirements for medical writing are witnessing continuous growth influenced in good portion by the mounting government scrutiny and… Read More

Have a business query? Let’s talk.

Subscribe to cro.pepgra Newsletter